Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-03526299 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-03526299 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Fluticasone propionate | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-03526299 | DRUG | Inhaled, two doses 4 hours apart |
| Placebo | DRUG | Inhaled, two doses 4 hours apart |
| Fluticasone propionate | DRUG | Inhaled |
Inclusion Criteria: * Males and females 18-60 years * Mild asthma * Atopic to allergens Exclusion Criteria: * Unstable asthma * Smokers or recent ex-smokers * Recent allergen challenge
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
PF-03526299 is an investigational small molecule developed by Pfizer, Inc. for asthma, a respiratory condition. It was studied in a Phase 1 clinical trial that has been completed. It is not an approved therapy and remains in clinical development.
PF-03526299 was studied for use in asthma, with a Phase 1 trial evaluating its effect on lung function following an allergen challenge in asthmatic subjects. The trial enrolled 29 adults aged 18 years and older in the United Kingdom. It is investigational and not approved for any use.
Pfizer, Inc. develops PF-03526299. Pfizer trades on the New York Stock Exchange under the ticker PFE. The company sponsored the Phase 1 asthma study of the compound.
PF-03526299 is in Phase 1 clinical development. Its only recorded trial, NCT00877539, was a completed Phase 1 study in asthma. The compound is investigational and has not been approved by the FDA.
PF-03526299 has been studied in one clinical trial, NCT00877539, titled a study to assess the effect of PF-03526299 on lung function following an allergen challenge in asthmatic subjects. The Phase 1 trial was completed, enrolled 29 participants, and took place in the United Kingdom.
The Phase 1 trial NCT00877539 was randomized, double blind, and placebo controlled, enrolling 29 adults with asthma in the United Kingdom. It assessed the effect of PF-03526299 on lung function after an allergen challenge. The study is completed.